DK2279200T3 - Biologisk aktive peptider - Google Patents
Biologisk aktive peptider Download PDFInfo
- Publication number
- DK2279200T3 DK2279200T3 DK09743243.9T DK09743243T DK2279200T3 DK 2279200 T3 DK2279200 T3 DK 2279200T3 DK 09743243 T DK09743243 T DK 09743243T DK 2279200 T3 DK2279200 T3 DK 2279200T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- val trp
- prt
- artificial sequence
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Peptid eller peptidderivat omfattende: (i) WDLYFEIVW; eller (ii) en aminosyresekvens-variant omfattende en, to, tre eller fire L-aminosyresubstitutioner i WDLYFEIVW; hvor aminosyresekvens-varianten omfatter X1X2X3YX4EX5X6X7, hvor Xi er W, L eller P, X2 er D eller S, X3 er L eller F, X4 er F, Phg, L, Ebw, Pff, Thi, 1 Ni, Hfe, Ece eller Cha, Xs er I eller F, Χβ er S, V eller G og X7 er W eller L, eller (iii) retro-invers-varianten af peptidet eller peptid-derivatet af en af delene (i) og (ii), hvor peptidet eller peptid-derivatet har prokoagulatorisk aktivitet.
2. Peptidet eller peptid-derivatet ifølge krav 1, hvor aminosyresekvens-varianten omfatter en aminosyresekvens omfattende X1X2X3YX4EX5X6X7, hvor X3 er L og Xs er I.
3. Peptidet eller peptid-derivatet ifølge krav 1, hvor aminosyresekvens-varianten omfatter en aminosyresekvens omfattende X1X2X3YX4EX5X6X7, hvor Xi er W eller L, X2 er D eller S, X3 er L eller F, X4 er F, Phg eller L, Xs er I eller F, Χβ er S, V eller G og X7 er W eller L.
4. Peptidet eller peptid-derivatet ifølge krav 1 omfattende: (1) RMEFDVWDLYFEIVW; eller (2) RMKFDVWDLYFEIVW; eller (3) en aminosyresekvens-variant RMEFDVWDLYFEIVW eller RMKFDVWDLYFEIVW omfattende mellem én og seks aminosyresubstitutioner af RMEFDVWDLYFEIVW eller RMKFDVWDLYFEIVW, hvor når varianten omfatter én, to, tre, eller fire aminosyresubstitutioner i WDLYFEIVW, omfatter denne aminosyresekvens-variant X1X2X3YX4EX5X6X7, hvor den ene, to, tre eller fire substitutioner er substitutioner lokaliseret ved Xi, X2, X3, X4, X5, Xe og/eller X7; hvor Xi er W, L eller P, X2 er D eller S, X3 er L eller F, X4 er F, Phg, L, Ebw, Pff, Thi, 1 Ni, Hfe, Ece eller Cha, Xs er I eller F, Xe er S, V eller G og X7 er W eller L
5. Peptidet eller peptid-derivatet ifølge krav 4 hvor aminosyresekvens-varianten omfatter en aminosyresekvens omfattende X8X9X10FDVX1X2X3YX4EX5X6X7, hvor Xe er R eller P, X9 er M, Nva, Moo, N, Nle, Meo, Q eller Eag, X10 er E, K eller D, Xi er W, L eller P, X2 er D eller S, X3 er L eller F, X4 er F, Phg, L, Ebw, Pff, Thi, 1 Ni, Hfe, Ece, Cha, Xs er I eller F, Xe er S, V eller G og X7 er W eller L.
6. Peptidet eller peptid-derivatet ifølge krav 5, hvor aminosyresekvens-varianten omfatter en aminosyresekvens omfattende X8X9X10FDVX1X2X3YX4EX5X6X7, hvor Xe er R eller P, Xg er M eller Nva, X10 er E, K eller D, Xi er W eller L, X2 er D eller S, X3 er L eller F, X4 er F, Phg eller L, Xs er I eller F, Xe er S, V eller G og X7 er W eller L.
7. Peptid-derivatet ifølge krav 1, der er acetyleret ved N-terminus, amideret ved C-terminus og/eller PEGyleret ved den ene terminus.
8. Peptidet eller peptid-derivatet ifølge krav 1 der er cyklisk.
9. Peptidet eller peptid-derivatet ifølge krav 1 omfattende eller bestående af: AC-RMKFDVWDLYFEIVW-NH2, AC-PMKFDVWDLYFEIVW-NH2, Ac-RMDFDVWDLYFEIVW-NH2, AC-RMEFDVWDLYFEIVW-NH2, Ac-WDLYFEIVW-NH2, Ac-WDLYFEIVWE, Ac-WDLYFEIVW-ttds-E, ttds-RMEFDVWDLYFEIVW-ttdS-NH2, ERMEFDVWDLYFEIVW-NH2, ER(Nva)EFDVWDLYFEIVW-NH2, ttds-RMEFDVWDLY(Phg)EIVW-ttds-NH2, Ac-WSLYFEIVWE, Ac-WDLYFEISW-ttds-E, PEG5000-RMKFDVWDLYFEIVW-NH2, PEG5000-WSLYFEIVWE), PEG5000-ERMEFDVWDLYFEIVW-NH2, AC-VWDLYFEIVW-NH2, Ac-FDVWDLYFEIVW-NH2, EWDLYFEIVW-NH2, E-ttds-WDLYFEIVW-NH2, Ac-WDLYFEIVW-ttdS-E-NH2, Ac-RMEFDVWDLYFEIVW, RMEFDVWDLYFEIVW, Ac-K-ttds-RMEFDVWDLYFEIVW-NH2, Ac-RMEFDVWDLYFEIVWK, Ac- RMEFDVWDLYFEIVWK-NH2, Ac-RMEFDVWDLYFEIVW-ttds-K-NH2, Ac-WDLYFEISWE, Ac-WDLYLEIVWE, Ac-WDLYFEIVLE, WDLYFEIVW, RMEFDVWDLYFEIVW-NH2, Ac-RMEFDVWDLYFEIVW-ttds-NH2, Ac-KRMEFDVWDLYFEIVW-NH2, K-ttds-RMEFDVWDLYFEIVW-NH2, Ac-RMEFDVWDLYFEIVW-ttds-K, Ac-LDLYFEIVW-ttds-E, Ac-WDLYFEIVL-ttds-E, E-RMEFDVLDLYFEIVW-NH2, E-RMEFDVWDLYFEIVL-NH2, Ac-WDFYFEIVWE, Ac-WDLYFEFVWE, Ac-LDLYFEIVWE, Ac-WDLYFEIGWE, Ac-WDLYLEISLE, Ac-WDLYXEIVLE, Ac-WSLYXEIVWE, Ac-LDLYFEIVLE, Ac-LDLYFEISLE, Ac-LDLYXEISWE, Ac-LSLYFEIVWE, Ac-LSLYFEIVLE, Ac-LSLYFEISLE, Ac-WDLYFEIVW-ttds-K, AC-DVWDLYFEIVW-NH2, Ac-wviefyldwvdfkmr-NH2, Ac-WDLYFEIVW, Ac-ttds-WDLYFEIVW-NH2, ttds-WDLYFEIVW-NH2, Ac-WDLYFEIVW-ttds-NH2, Ac-ttds-WDLYFEIVW-ttds-NH2, ttds-WDLYFEIVW-ttds, ttds-WDLYFEIVW-ttds-NH2, AC-KWDLYFEIVW-NH2, Ac-K-ttdS-WDLYFEIVW-NH2, Ac-WDLYFEIVWK, AC-WDLYFEIVWK-NH2, E-R(Moo)EFDVWDLYFEIVW-NH2, E-RNEFDVWDLYFEIVW-NH2, ttds-RMEFDVWDLY(Ebw)EIVW-ttds-NH2, ttds-RMEFDVWDLY(Pff)EIVW-ttds-NH2, Ac-PDLYFEIVWE, Ac-LSLYLEIVLE, Ac-LSLYLEISLE, Ac-LSLYXEIVLE, Ac-WDLYFEIVW-ttds-K-NH2, E-PMKFDVWDLYFEIVW-NH2, ttds-RMDFDVWDLYFEIVW-ttds-NH2, PEG5000-RMKFDVWDLYFEIVW-NH2, WDLYFEIVW-NH2, KRMEFDVWDLYFEIVW-NH2, ttd S- P M KFD V W D LYFE IV W -ttds-NH2, E-RMDFDVWDLYFEIVW-NH2, (Coh)-ttds-RMEFDVWDLYFEIVW-ttds-NH2, Glucosyl-aminooxyacetyl-ttds-RMEFDVWDLYFEIVW-ttds-NH2, Ac-P(Moo)KFDVWDLYFEIVW-NH2, Ac-P(Nle)KFDVWDLYFEIVW-NH2, Ac-PNKFDVWDLYFEIVW-NH2, Ac-R(Moo)DFDVWDLYFEIVW-NH2, Ac-R(Nle)DFDVWDLYFEIVW-NH2, AC-RNDFDVWDLYFEIVW-NH2, ttds-R(Nle)EFDVWDLYFEIVW-ttdS-NH2, ttds-RNEFDVWDLYFEIVW-ttds-NH2, E-R(Nle)EFDVWDLYFEIVW-NH2, E-R(Meo)EFDVWDLYFEIVW-NH2, E-RQEFDVWDLYFEIVW-NH2, E-R(Eag)EFDVWDLYFEIVW-NH2, ttds-RMEFDVWDLY(Thi)EIVW-ttds-NH2, ttds-RMEFDVWDLY(lNi)EIVW-ttds-NH2, ttds-RMEFDVWDLY(Hfe)EIVW-ttds-NH2, ttds-RMEFDVWDLY(Ece)EIVW-ttds-NH2, ttds-RMEFDVWDLY(Cha)EIVW-ttds-NH2, KWDLYFEIVW-NH2, eller K-ftds-WDLYFEIVW-NH2, hvor -ttds- er 4,7,10-trioxa-l,13-tridecandiamin, (Nva) er norvalin, (Phg) er phenylglycin, (Coh) er cysteinsyre, (Moo) er methioninsulfon, (Ebw) er 3,3-diphenylalanin, (Pff) er 4'-fluorphenyl-alanin, (Nle) er norleucin, (Meo) er methioninsulfoxid, (Eag) er propargylglycin, (Thi) er 2-thienylalanin, (INi) er 1-naphthyl-alanin; (Hfe) er homophenylalanin, (Ece) er s-benzyl-L-cystein, (Cha) er cyclohexylalanin.
10. Dobbeltpeptid omfattende et første peptid eller første peptid-derivat som defineret i krav 1 konjugeret til et andet peptid eller andet peptid-derivat som defineret i et hvilket som helst af de foregående krav, hvor det første peptid eller første peptid-derivat kan være det samme som eller forskelligt fra det andet peptid eller andet peptid-derivat, og hvor dobbeltpeptidet har prokoagulatorisk aktivitet.
11. Peptidet eller peptid-derivatet ifølge krav 1, kendetegnet ved én eller flere af følgende: (i) peptidet eller peptid-derivatet har en molekylvægt på mellem 0,5 og 3,5kD; (ii) den prokoagulatoriske aktivitet er en thrombin generationstid på 25, 50 eller 100 μΜ af peptidet eller peptid-derivatet ækvivalent til det på mindst 100 mU/ml_ Factor Eight Inhibitor Bypassing Activity (FEIBA), mindst 300 mU/mL FEIBA, mindst 900 mU/ml_ FEIBA eller mindst 1200 mll/mL FEIBA i det Defined Intrinsic Thrombin Generation Assay; (iii) den prokoagulatoriske aktivitet er en thrombin generationstid på 25, 50 eller 100 μΜ af peptidet eller peptid-derivatet i et Defined Intrinsic Thrombin Generation Assay der topper indenfor 30 minutter, indenfor 15 minutter eller indenfor 10 minutter; (iv) peptidet eller peptid-derivatet kan mindst delvist kompensere for fraværet af biologisk aktivt FVIII når det administreres i en dyremodel af alvorlig human hæmofili A; (v) peptidet eller peptid-derivatet har en stabilitet i human plasma ved 30 minutter på mindst 50%, mindst 70%, mindst 80% eller mindst 90%; eller (vi) peptidet eller peptid-derivatet har en vandig opløselighed i phosphatbufferet saltvand pH 7,4 på mindst 25 μΜ, mindst 60 pM eller mindst 100 pM.
12. Farmaceutisk sammensætning omfattende peptidet eller peptid-derivatet ifølge et hvilket som helst af kravene 1 til 11 og én eller flere farmaceutisk acceptable excipienser, bærere og/eller fortyndingsmidler, eventuelt hvor den farmaceutiske sammensætning er egnet til subkutan, nasal, bukkal, oral, intravenøs eller pulmonær administration.
13. Peptidet eller peptid-derivatet ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i medicin, eventuelt, til anvendelse i behandling af en patient med en deficiens i FV, FVII, FVIII, FX og/eller FXI, eventuelt hvor patienten har inhibitorpeptider mod FV, FVII, FVIII, FX og/eller FXI.
14. Anvendelse af et peptid eller peptid-derivat ifølge et hvilket som helst af kravene 1 til 11 i fremstillingen af et medikament til behandlingen afen patient med en deficiens i FV, FVII, FVIII, FX og/eller FXI, eventuelt hvor patienten har inhibitor-antistoffer mod FV, FVII, FVIII, FX og/eller FXI.
15. Fremgangsmåde til fremstilling af peptidet eller peptid-derivatet ifølge et hvilket som helst af kravene 1 til 11 ved fastfase-syntese.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US932608P | 2008-04-17 | 2008-04-17 | |
| US11305508P | 2008-11-10 | 2008-11-10 | |
| PCT/US2009/040857 WO2009137256A1 (en) | 2008-04-17 | 2009-04-16 | Biologically active peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2279200T3 true DK2279200T3 (da) | 2016-08-22 |
Family
ID=40887122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09743243.9T DK2279200T3 (da) | 2008-04-17 | 2009-04-16 | Biologisk aktive peptider |
| DK16172509.8T DK3115370T3 (da) | 2008-04-17 | 2009-04-16 | Biologisk aktive peptider |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16172509.8T DK3115370T3 (da) | 2008-04-17 | 2009-04-16 | Biologisk aktive peptider |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US8563688B2 (da) |
| EP (2) | EP2279200B1 (da) |
| JP (3) | JP6038452B2 (da) |
| KR (2) | KR101434712B1 (da) |
| CN (2) | CN105524163A (da) |
| AR (1) | AR071478A1 (da) |
| AU (1) | AU2009244635B2 (da) |
| BR (1) | BRPI0911203A2 (da) |
| CA (1) | CA2721694C (da) |
| DK (2) | DK2279200T3 (da) |
| ES (2) | ES2594706T3 (da) |
| HK (2) | HK1154255A1 (da) |
| MX (1) | MX2010011397A (da) |
| NZ (1) | NZ588200A (da) |
| PL (1) | PL2279200T3 (da) |
| PT (1) | PT2279200T (da) |
| SG (2) | SG10201608071YA (da) |
| TW (2) | TWI573806B (da) |
| WO (1) | WO2009137256A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI573806B (zh) * | 2008-04-17 | 2017-03-11 | 巴克斯歐塔公司 | 生物活性胜肽 |
| WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
| WO2012012444A2 (en) | 2010-07-19 | 2012-01-26 | Dolby Laboratories Licensing Corporation | Enhancement methods for sampled and multiplexed image and video data |
| AU2012267484B2 (en) | 2011-06-10 | 2017-03-23 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
| HUE043537T2 (hu) | 2012-02-15 | 2019-08-28 | Bioverativ Therapeutics Inc | Rekombináns VIII faktor fehérjék |
| RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
| ES2856338T3 (es) * | 2013-06-11 | 2021-09-27 | Cj Cheiljedang Corp | Microorganismo que produce L-isoleucina y método de preparación de L-isoleucina mediante el uso del mismo |
| WO2015023894A1 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| US20160039876A1 (en) | 2014-03-28 | 2016-02-11 | Claresa Levetan | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide |
| JP6484468B2 (ja) * | 2014-06-03 | 2019-03-13 | ＡｖａｎＳｔｒａｔｅ株式会社 | ガラス板製造方法およびガラス板製造装置 |
| GB201410507D0 (en) * | 2014-06-12 | 2014-07-30 | Univ Bath | Drug delivery enhancement agents |
| EP3331608A4 (en) | 2015-08-03 | 2019-05-01 | Bioverativ Therapeutics Inc. | FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME |
| CA3038292A1 (en) | 2016-09-28 | 2018-04-05 | Cohbar, Inc. | Therapeutic mots-c related peptides |
| MX2019009063A (es) | 2017-01-31 | 2019-10-21 | Bioverativ Therapeutics Inc | Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447356A (en) * | 1981-04-17 | 1984-05-08 | Olivera Baldomero M | Conotoxins |
| IT1190891B (it) | 1982-06-24 | 1988-02-24 | Anic Spa | Metodo per la sintesi in fase solida di polipeptidi retroinvertiti |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| JPH0725794B2 (ja) * | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| EP0693924B2 (en) | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6005166A (en) * | 1994-12-30 | 1999-12-21 | Seminis Vegetable Seeds, Inc. | Papaya ringspot virus replicase gene |
| US5532153A (en) * | 1995-03-23 | 1996-07-02 | New England Biolabs, Inc. | Method for cloning and producing the SacI restriction endonuclease |
| US7279548B2 (en) * | 1996-04-03 | 2007-10-09 | Cytogen Corporation | Identification and isolation of novel polypeptides having WW domains and methods of using same |
| US6197526B1 (en) * | 1999-01-04 | 2001-03-06 | Dyax Corp. | Polypeptides for binding human factor VIII and fragments of human factor VIII |
| US7109170B2 (en) * | 1999-06-16 | 2006-09-19 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
| US6624289B1 (en) * | 1999-06-16 | 2003-09-23 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
| CA2373735A1 (en) * | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Fviia antagonists |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| AU2065801A (en) * | 1999-12-06 | 2001-06-12 | Panacea Pharmaceuticals, Llc | Passive desensitization |
| CA2398136A1 (en) * | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| WO2002092623A1 (en) * | 2001-05-11 | 2002-11-21 | Research Development Foundation | INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF |
| FR2830865B1 (fr) * | 2001-10-17 | 2004-10-22 | Centre Nat Rech Scient | Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes |
| US20060204503A1 (en) * | 2005-01-31 | 2006-09-14 | Biogen Idec Ma Inc. | Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors |
| CN101379077A (zh) | 2005-12-07 | 2009-03-04 | 夏洛特·豪泽 | 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体 |
| KR20080090489A (ko) | 2006-01-04 | 2008-10-08 | 두-쿱 테크놀로지스 리미티드 | 살균제 조성물 및 그 사용 방법 |
| TWI573806B (zh) * | 2008-04-17 | 2017-03-11 | 巴克斯歐塔公司 | 生物活性胜肽 |
-
2009
- 2009-04-15 TW TW103127214A patent/TWI573806B/zh active
- 2009-04-15 TW TW098112448A patent/TWI541020B/zh active
- 2009-04-15 AR ARP090101328A patent/AR071478A1/es active IP Right Grant
- 2009-04-16 SG SG10201608071YA patent/SG10201608071YA/en unknown
- 2009-04-16 BR BRPI0911203A patent/BRPI0911203A2/pt not_active Application Discontinuation
- 2009-04-16 SG SG10201809286XA patent/SG10201809286XA/en unknown
- 2009-04-16 EP EP09743243.9A patent/EP2279200B1/en active Active
- 2009-04-16 ES ES09743243.9T patent/ES2594706T3/es active Active
- 2009-04-16 MX MX2010011397A patent/MX2010011397A/es active IP Right Grant
- 2009-04-16 WO PCT/US2009/040857 patent/WO2009137256A1/en active Application Filing
- 2009-04-16 US US12/425,277 patent/US8563688B2/en active Active
- 2009-04-16 JP JP2011505212A patent/JP6038452B2/ja active Active
- 2009-04-16 KR KR1020107025687A patent/KR101434712B1/ko active IP Right Grant
- 2009-04-16 CN CN201610040575.5A patent/CN105524163A/zh active Pending
- 2009-04-16 EP EP16172509.8A patent/EP3115370B1/en active Active
- 2009-04-16 PT PT97432439T patent/PT2279200T/pt unknown
- 2009-04-16 NZ NZ588200A patent/NZ588200A/xx unknown
- 2009-04-16 DK DK09743243.9T patent/DK2279200T3/da active
- 2009-04-16 AU AU2009244635A patent/AU2009244635B2/en active Active
- 2009-04-16 PL PL09743243T patent/PL2279200T3/pl unknown
- 2009-04-16 KR KR1020137024826A patent/KR101606248B1/ko active IP Right Grant
- 2009-04-16 CA CA2721694A patent/CA2721694C/en active Active
- 2009-04-16 ES ES16172509T patent/ES2739676T3/es active Active
- 2009-04-16 CN CN200980114502.4A patent/CN102007140B/zh active Active
- 2009-04-16 DK DK16172509.8T patent/DK3115370T3/da active
-
2011
- 2011-08-03 HK HK11108062.3A patent/HK1154255A1/zh unknown
- 2011-09-21 US US13/238,751 patent/US8822638B2/en active Active
-
2013
- 2013-12-20 JP JP2013263345A patent/JP5977223B2/ja active Active
-
2014
- 2014-07-24 US US14/340,231 patent/US9206234B2/en active Active
-
2015
- 2015-11-13 US US14/941,163 patent/US9598464B2/en active Active
-
2016
- 2016-07-21 JP JP2016143368A patent/JP2017019797A/ja active Pending
- 2016-10-19 HK HK16112064.8A patent/HK1223946A1/zh unknown
-
2017
- 2017-02-27 US US15/443,949 patent/US10287319B2/en active Active
-
2019
- 2019-03-20 US US16/359,763 patent/US10822376B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10822376B2 (en) | Biologically active peptides | |
| EP2717898B1 (en) | Pro-coagulant compounds and methods of use thereof | |
| AU2019202888B2 (en) | Biologically active peptides | |
| AU2012205202B2 (en) | Biologically Active Peptides |